TAIPEI, Taiwan – Twi Biotechnology Inc., the drug development arm of Taipei, Taiwan-headquartered generics firm Twi Pharmaceutical Inc., recently received orphan drug designation from the FDA for the use of its AC-201 drug candidate to topically treat epidermolysis bullosa (EB).